An Exploration of Dissolution Tests for Inhalation Aerosols.
aerosol
budesonide
cascade impactor
dissolution test
Journal
AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
30
05
2024
accepted:
19
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
This study aimed to establish a feasible dissolution method for inhalation aerosols. A method of collecting fine particles was investigated to capture aerosol particles less than 4 μm in diameter for dissolution tests. This dose collection method enabled the aerosol particles to be uniformly distributed on the glass fiber filter, thus considerably reducing particle agglomeration. Budesonide was used as a model drug. The aerodynamic particle size distribution (APSD) of the meter-dose inhaler (MDI) was compared by replacing actuators with different orifice sizes. Dissolution tests were conducted on fine particle doses collected using various actuators, and the dissolution profiles were modeled. The fine particle dose decreased with an increasing orifice size of the actuator. Actuators with different orifice sizes would affect the dissolution behavior of inhaled drugs. This finding was supported by similarity factor f
Identifiants
pubmed: 39354249
doi: 10.1208/s12249-024-02951-2
pii: 10.1208/s12249-024-02951-2
doi:
Substances chimiques
Aerosols
0
Budesonide
51333-22-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
230Informations de copyright
© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Rohrschneider M, Bhagwat S, Krampe R, Michler V, Breitkreutz J, Hochhaus G. Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant. Mol Pharm. 2015;12(8):2618–24.
doi: 10.1021/acs.molpharmaceut.5b00221
pubmed: 26091361
Bäckman P, Adelmann H, Petersson G, Jones CB. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther. 2014;95:509–20.
doi: 10.1038/clpt.2014.27
pubmed: 24503626
Sonvico F, Chierici V, Varacca G, Quarta E, D’Angelo D, Forbes B, et al. RespiCellTM: An Innovative Dissolution Apparatus for Inhaled Products. Pharmaceutics. 2021;13(10):15 41. https://doi.org/10.3390/pharmaceutics13101541 .
Olsson B, Bäckman P. Mouth-throat models for realistic in vitro testing – a proposal for debate. In: Dalby RN, Byron PR, Peart J, et al., editors. Proceedings of respiratory drug delivery 2014.River Grove, IL: DHI Publishing; 2014;1. pp. 287–94.
Radivojev S, Luschin-Ebengreuth G, Pinto JT, Laggner P, Cavecchi A, Cesari N, et al. Impact of simulated lung fluid components on the solubility of inhaled drugs and predicted in vivo performance. Int J Pharm. 2021;606: 120893.
doi: 10.1016/j.ijpharm.2021.120893
pubmed: 34274456
Ayoub Y, Buzgeia A, Almousawi G, Mazhar HRA, Alzouebi B, Gopalan RC, et al. In-Vitro In-Vivo Correlation (IVIVC) of Inhaled Products Using Twin Stage Impinger. J Pharm Sci. 2022;111(2):395–402.
doi: 10.1016/j.xphs.2021.09.042
pubmed: 34599997
Pilcer G, Rosière R, Traina K, Sebti T, Vanderbist F, Amighi K. New Co-Spray-Dried Tobramycin Nanoparticles Clarithromycin Inhaled Powder Systems for Lung Infection Therapy in Cystic Fibrosis Patients. J Pharm Sci. 2013;102:1836–46.
doi: 10.1002/jps.23525
pubmed: 23568616
Mohan M, Lee S, Guo C, Peri SP, Doub WH. Evaluation of abbreviated impactor measurements (AIM) and efficient data analysis (EDA) for dry powder inhalers (DPIs) against the full resolution next generation impactor (NGI). AAPS PharmSciTech. 2017;18:1585–94.
doi: 10.1208/s12249-016-0625-9
pubmed: 27624069
Gray VA. Meeting report: AAPS workshop on inhalation product biopharmaceutical classification system development: challenges and opportunities. Dissolution Technol. 2015;22:52–5. https://doi.org/10.14227/DT220315P52 .
doi: 10.14227/DT220315P52
Tay JYS, Liew CV, Heng PWS. Dissolution of fine particle fraction fromtruncated Anderson cascade impactor with an enhancer cell. Int J Pharm. 2018;545:45–50.
doi: 10.1016/j.ijpharm.2018.04.048
pubmed: 29689370
Tyfa Z, JÓŹwik P, Obidowski D, Reorowicz P, Jodko D, Kapka, K, et al. Inhaled drug airflow patterns and particles deposition in the paediatric respiratory tract. Acta Bioeng Biomech. 2020;22(2):101-10.
May S, Kind S, Jensen B, Wolkenhauer M, Schneider M, Lehr CM. Miniature in vitro dissolution testing of powders for inhalation. Dissolution Technol. 2015;22:40–51.
doi: 10.14227/DT220315P40
Gerde P, Malmlöf M, Havsborn L, Sjöberg CO, Ewing P, Eirefelt S, et al. DissolvIt : an in vitro method for simulating the dissolution and absorption of inhaled dry powder drugs in the lungs. Assay Drug Dev Technol. 2017;15:77–88.
doi: 10.1089/adt.2017.779
pubmed: 28322599
Radivojev S, Zellnitz S, Paudel A, Fröhlich E. Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs. Int J Pharm. 2019;556:45–56.
doi: 10.1016/j.ijpharm.2018.11.072
pubmed: 30529665
Forbes B, Hauet-Richer N, Buttini F. Dissolution: a critical performance characteristic of inhaled products? Pulmonary DrugDelivery: Advantages and Challenges.2015.pp. 223–40.
Floroiu A, Klein M, Krämer J, Lehr CM. Towards Standardized Dissolution Techniques for In Vitro Performance Testing of Dry Powder Inhalers. Dissolut Technol. 2018;25(3):6–8.
doi: 10.14227/DT250318P6
Riley T, Christopher D, Arp J, Casazza A, Colombani A, Cooper A, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS PharmSciTech. 2012;13:978–89.
doi: 10.1208/s12249-012-9822-3
pubmed: 22798037
pmcid: 3429693
FDA. Draft Guidance on Budesonide; Formoterol Fumarate; Glycopyrrolate. 2024. https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm . Accessed 15 Feb 2024.
Horhota ST. Evaluation of comparative performance of orally inhaled drug products in view of the classical bioequivalence paradigms: an analysis of the current scientific and regulatory dilemmas of inhaler evaluation. J Aerosol Med Pulm Drug Deliv. 2014;27:408–13.
doi: 10.1089/jamp.2014.1144
pubmed: 25237840
Huang Z, Lin L, McGoverin C, Liu H, Wang L, Zhou QT, et al. Dry powder inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro dissolution and in-vivo distribution is necessary. Int J Pharm. 2018;551(1–2):103–10.
doi: 10.1016/j.ijpharm.2018.09.018
pubmed: 30217767
Lin L, Quan G, Peng T, Huang Z, Singh V, Lu M, et al. Development of fine solid-crystal suspension with enhanced solubility, stability, and aerosolization performance for dry powder inhalation. Int J Pharm. 2017;533(1):84–92.
doi: 10.1016/j.ijpharm.2017.09.024
pubmed: 28903066
United States Pharmacopeia. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers (Chapter 601). US Pharmacopeial Convention. US Pharmacopeia 30−National Formulary. 2009;25.
Hassoun M, Royall PG, Parry M, Harvey RD, Forbes B. Design and development of a biorelevant simulated human lung fluid. J Drug Deliv Sci Technol. 2018;47:485–91.
doi: 10.1016/j.jddst.2018.08.006
pubmed: 30283501
pmcid: 6156579
Ie F, Ji S, Cheng Z. In vitro dissolution similarity factor (f) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example. Eur J Pharm Sci. 2015;66:163–72.
doi: 10.1016/j.ejps.2014.10.002
Price R, Shur J, Ganley W, Farias G, Fotaki N, Conti DS, et al. Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products. AAPS J. 2020;22(2):47.
doi: 10.1208/s12248-020-0422-y
pubmed: 32060670
Salama R, Traini D, Chan H-K, Young PM. Preparation and characterisation of controlled release co-spray dried drug–polymer microparticles for inhalation. 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharmacol Biopharm. 2008;70:145–52.
Weiss M, Siegmund W. Dependence of Bioavailability on Mean Absorption Time: What Does It Tell Us? AAPS J. 2023;25(3):36.
doi: 10.1208/s12248-023-00803-8
pubmed: 37016156
Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of Budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7(10):1839–44.
doi: 10.1183/09031936.94.07101839
pubmed: 7828694
Kumar R, Mehta P, Shankar KR, Rajora MAK, Mishra YK, Mostafavi E, et al. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications. Pharm Res. 2022;39(11):2831–55.
doi: 10.1007/s11095-022-03286-y
pubmed: 35552983
pmcid: 9097569
Son YJ, Horng M, Copley M, McConville JT. Optimization of an in vitro dissolution test method for inhalation formulations. Dissol Technol. 2010;17(2):6–13.
doi: 10.14227/DT170210P6
Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv. 2009;6(9):941–59.
doi: 10.1517/17425240903117244
pubmed: 19637979
Hastedt JE, Bäckman P, Clark AR, Doub W, Hickey A, Hochhaus G. Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop, March 16–17, 2015, Baltimore. MD AAPS Open. 2016;2:1–20.
doi: 10.1186/s41120-015-0002-x
Eedara BB, Bastola R, Das SC. Dissolution and Absorption of Inhaled Drug Particles in the Lungs. Pharmaceutics. 2022;14(12):2667.
doi: 10.3390/pharmaceutics14122667
pubmed: 36559160
pmcid: 9781681
Mathias NR, Timoszyk J, Stetsko PI, Megill JR, Smith RL, Wall DA. Permeability characteristics of Calu-3 human bronchial epithelial cells: in vitro/in vivo correlation to predict lung absorption in rats. J Drug Target. 2002;10:31–40.
doi: 10.1080/10611860290007504
Amini E, Kurumaddali A, Bhagwat S, Berger SM, Hochhaus G. Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches. Pharmaceutics. 2021;13(8):1109.
doi: 10.3390/pharmaceutics13081109
pubmed: 34452069
pmcid: 8398439
Bielski E, Conti DS, Oguntimein O, Sheth P, Hallinger M, Svensson M, et al. FDA. The Effects of Formulation Factors and Actuator Design on Mometasone Furoate Metered Dose Inhaler In Vitro Aerosolization Performance. https://www.fda.gov/science-research/fda-science-forum . Accessed 29 Oct 2020.
Chen Y, Young PM, Murphy S, Fletcher DF, Long E, Lewis D, et al. High-speed laser image analysis of plume angles for pressurised metered dose inhalers: The effect of nozzle geometry. AAPS Pharm Sci Tech. 2017;18(3):782–9.
doi: 10.1208/s12249-016-0564-5
Mitchell J, Dolovich MB. Clinically relevant test methods to establish in vitro equivalence for spacers and valved holding In Vitro Testing for Orally Inhaled Products chambers used with pressurized metered dose inhalers (pMDIs). J Aerosol Med Pulmon Drug Deliv. 2012;25:217–42.
doi: 10.1089/jamp.2011.0933
Kinnunen H, Hebbink G, Peters H, Shur J, Price R. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulation using artificial neural networks. AAPS Pharm Sci Tech. 2014;15:1009–20.
doi: 10.1208/s12249-014-0108-9
Das S, Ravindra S, Behara B, Bulitta J, Morton D, Larson I, et al. Powder strength distributions for understanding the agglomeration of lactose powders. Pharm Res. 2012;29:2926–35.
doi: 10.1007/s11095-012-0799-0
pubmed: 22695732
Shur J, Harris H, Jones M, Kaerger S, Price R. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm Res. 2008;25:1931–40.
doi: 10.1007/s11095-008-9538-y
Price R. Critical device and formulation controls required in achieving in vitro comparability of OIPs. IPAC-RS Orlando Inhalation Conference.2014. http://ipacrs.org/assets/uploads/outputs/04-Day_2_OIC_2014_Price . Accessed 20 Mar 2014.
May S, Jensen B, Weiler C, Wolkenhauer M, Schneider M. Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles. Pharm Res. 2014;31(11):3211–24.
doi: 10.1007/s11095-014-1413-4
pubmed: 24852894
Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm. 2003;255:175–87.
doi: 10.1016/S0378-5173(03)00091-7
pubmed: 12672613
Costa PC, Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–33.
doi: 10.1016/S0928-0987(01)00095-1
pubmed: 11297896
de Jesús Martín-Camacho U, Rodríguez-Barajas N, Alberto Sánchez-Burgos J, and Pérez-Larios A. Weibull β value for the discernment of drug release mechanism of PLGA particles. Int I Pharm. 2023;123017.
Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 2006;309:44–50.
doi: 10.1016/j.ijpharm.2005.10.044
pubmed: 16376033
Qureshi SA. In vitro-in vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing a simple and practical approach. Open Drug Del J. 2010;4:38–47.
doi: 10.2174/1874126601004020038
Derendorf H, Hochhaus G, Meibohm B, Mcollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4):S440–6.
doi: 10.1016/S0091-6749(98)70156-3
pubmed: 9563369
Bhagwat S, Schilling U, Chen MJ, Wei X, Delvadia R, Absar M, et al. Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. Pharm Res. 2017;34(12):2541–56.
doi: 10.1007/s11095-017-2235-y
pubmed: 28799097